Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $81.88

Gilead Sciences, Inc. (NASDAQ:GILD) has been given an average rating of “Hold” by the twenty ratings firms that are covering the company, MarketBeat.com reports. Twelve investment analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $81.94.

GILD has been the topic of several research analyst reports. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 price objective on shares of Gilead Sciences in a report on Friday, August 9th. Finally, Royal Bank of Canada increased their target price on shares of Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a report on Friday, August 9th.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GILD. Quarry LP bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $43,000. Sunbelt Securities Inc. increased its stake in Gilead Sciences by 35.1% in the 2nd quarter. Sunbelt Securities Inc. now owns 15,678 shares of the biopharmaceutical company’s stock worth $1,076,000 after purchasing an additional 4,075 shares in the last quarter. Magnolia Capital Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter worth about $461,000. Creative Planning raised its holdings in Gilead Sciences by 8.4% during the 2nd quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock worth $12,939,000 after buying an additional 14,544 shares during the period. Finally, Doheny Asset Management CA purchased a new stake in Gilead Sciences during the second quarter valued at about $2,688,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.8 %

NASDAQ GILD opened at $73.78 on Monday. The company has a market capitalization of $91.92 billion, a price-to-earnings ratio of 204.94, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $87.86. The company’s fifty day moving average price is $70.80 and its two-hundred day moving average price is $70.20.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 4.17%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.